Table 1.
Non-sedated and sedated patients taking antipsychotic drugs
| Drug\stable dose period | 5 days | 10 days | ||||
|---|---|---|---|---|---|---|
| No sedation | Sedation | p-value | No sedation | Sedation | p-value | |
| Chlorprothixene | ||||||
| Mean dose | 92.56 | 122.67 | 0.005 | 94.14 | 121.14 | 0.003 |
| n (%) | 621 (82) | 133 (18) | 485 (70) | 211 (30) | ||
| Olanzapine | ||||||
| Mean dose | 14.32 | 18.33 | 0.01 | 14.07 | 17.28 | 0.005 |
| n (%) | 569 (83) | 117 (17) | 466 (71) | 191 (29) | ||
| Clozapine | ||||||
| Mean dose | 263.63 | 354.49 | 0.04 | 268.79 | 377.05 | 0.003 |
| n (%) | 188 (83) | 39 (17) | 163 (73) | 61 (27) | ||
| Quetiapine | ||||||
| Mean dose | 255.55 | 325.11 | 0.03 | 272.14 | 332.84 | 0.02 |
| n (%) | 545 (81) | 127 (19) | 480 (73) | 177 (27) | ||
| Risperidone | ||||||
| Mean dose | 2.68 | 2.97 | 0.22 | 2.80 | 2.96 | 0.38 |
| n (%) | 329 (82) | 74 (18) | 275 (72) | 106 (28) | ||
| Levomepromazine | ||||||
| Mean dose | 69.87 | 98.31 | 0.14 | 69.87 | 88.44 | 0.25 |
| n (%) | 139 (80) | 34 (20) | 114 (70) | 48 (30) | ||
| Zuclopenthixol | ||||||
| Mean dose | 10.58 | 13.83 | 0.16 | 11.60 | 12.00 | 0.82 |
| n (%) | 212 (88) | 29 (12) | 173 (77) | 51 (23) | ||
| Haloperidol | ||||||
| Mean dose | 7.90 | 4.04 | 0.007 | 7.81 | 6.08 | 0.31 |
| n (%) | 89 (88) | 12 (12) | 70 (80) | 18 (20) | ||
| Aripiprazole | ||||||
| Mean dose | 12.84 | 13.95 | 0.54 | 13.59 | 15.02 | 0.30 |
| n (%) | 219 (86) | 37 (14) | 192 (77) | 56 (23) | ||
| Ziprasidone | ||||||
| Mean dose | 94.17 | 118.82 | 0.09 | 101.28 | 125.00 | 0.04 |
| n (%) | 127 (79) | 34 (21) | 109 (73) | 40 (27) | ||
Distribution of non-sedated and sedated patients during the first stable dosage interval of 5 and 10 days after drug introduction. The ten most prescribed antipsychotics in descending number of total prescriptions in the study population